Ming Hou

机构：Shandong University, Jinan Central Hospital, Jining Traditional Chinese Medicine Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Qilu Hospital of Shandong University, Shandong First Medical University, Air Force Medical University · ORCID：0000-0001-6362-0483

发表论文 391 篇 · 总被引 10236 次 · h-index 52

代表论文

• Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP) (2024 · Autoimmunity Reviews · 被引 40)
• Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study (2024 · Blood · 被引 5)
• Ianalumab plus Eltrombopag in Immune Thrombocytopenia (2025 · New England Journal of Medicine · 被引 4)
• Inhibiting mTORC1 pathway by rapamycin restores the balance of CD8+ T cell subsets and reduces CD8+ T cell-mediated platelet destruction in immune thrombocytopenia (2025 · Thrombosis Research · 被引 4)
• CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia (2025 · British Journal of Haematology · 被引 4)
• Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment (2025 · Blood · 被引 3)